本文選題：胃癌 + X射線損傷交叉互補(bǔ)蛋白　； 參考：《山東醫(yī)藥》2017年08期

【摘要】：目的探討X射線損傷交叉互補(bǔ)蛋白1(XRCC1)Arg194Trp位點(diǎn)多態(tài)性與胃癌鉑類藥物化療敏感性的關(guān)系。方法選擇接受鉑類藥物化療的胃癌患者80例,采用聚合酶鏈?zhǔn)椒磻?yīng)-連接酶檢測反應(yīng)技術(shù)檢測XRCC1基因Arg194Trp位點(diǎn)基因型。所有患者術(shù)后接受以奧沙利鉑為主的一線化療方案,根據(jù)化療效果分為化療敏感者和化療耐藥者,分析XRCC1基因Arg194Trp位點(diǎn)多態(tài)性與化療敏感性的關(guān)系。結(jié)果 XRCC1基因Arg194Trp位點(diǎn)存在Arg/Arg、Arg/Trp、Trp/Trp三種基因型,分布頻率分別為42.5%(34/80)、50.0%(40/80)、7.5%(6/80);三種基因型分布滿足HardyWeiberg基因遺傳平衡定律,具有群體代表性。Arg/Arg、Arg/Trp、Trp/Trp基因型患者性別、年齡、組織類型、TNM分期、化療方案等臨床病理參數(shù)比較差異均無統(tǒng)計(jì)學(xué)意義(P均0.05)。80例患者中,化療敏感(完全緩解+部分緩解)39例(48.8%),耐藥(穩(wěn)定+進(jìn)展)41例(51.2%);Arg/Trp、Trp/Trp基因型者化療敏感率均顯著高于Arg/Arg者(P均0.05),Arg/Trp與Trp/Trp基因型患者化療敏感率比較差異無統(tǒng)計(jì)學(xué)意義(P0.05)。結(jié)論 XRCC1基因Arg194Trp位點(diǎn)多態(tài)性與胃癌患者鉑類藥物化療敏感性有關(guān);檢測Arg194Trp位點(diǎn)多態(tài)性可為胃癌化療的個(gè)體化用藥提供依據(jù)。
[Abstract]:Objective to investigate the relationship between 1(XRCC1)Arg194Trp polymorphism of X-ray injury cross-complementary protein and chemosensitivity of platinum drugs in gastric cancer. Methods A total of 80 patients with gastric cancer received chemotherapy with platinum drugs were selected to detect the genotypes of XRCC1 gene Arg194Trp loci by polymerase chain reaction-ligase assay. All patients were treated with oxaliplatin as the main first-line chemotherapy regimen. According to the effect of chemotherapy, the patients were divided into chemotherapy-sensitive and chemotherapeutic patients. The relationship between the polymorphism of Arg194Trp locus of XRCC1 gene and chemosensitivity was analyzed. Results there were three Arg / Arg / Arg / TrpTrpTrp genotypes in the Arg194Trp locus of the XRCC1 gene, and the distribution frequencies were 42.5% / 80% and 50.040 / 80%, respectively. The distribution of the three genotypes met the law of genetic balance of the HardyWeiberg gene, and the distribution of the three genotypes met the law of genetic balance of the HardyWeiberg gene. Argr / Argr Argr / ArgP / TrpTrpTrp genotype patients had sex, age, tissue type and stage of TNM. There was no significant difference in the clinicopathologic parameters of chemotherapy regimen between the two groups (P = 0.050.80). The chemosensitivity rate of 39 patients with complete remission and 41 patients with stable progression were significantly higher than that of patients with Arg/Arg. There was no significant difference in the rates of chemosensitivity between ARG / TRP and Trp/Trp genotypes (P 0.05). Conclusion the polymorphism of Arg194Trp locus of XRCC1 gene is related to the chemotherapeutic sensitivity of platinum-like drugs in gastric cancer patients, and the detection of Arg194Trp locus polymorphism may provide evidence for individualized chemotherapy of gastric cancer.
【作者單位】： 海南省人民醫(yī)院;福建醫(yī)科大學(xué)附屬第一醫(yī)院;
【基金】：海南省醫(yī)學(xué)科研立項(xiàng)課題(瓊衛(wèi)[2012]PT-17)
【分類號】：R735.2

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 李江奇;趙永勛;姜雷;元博;孫麗娜;梁富翔;馬守成;;中國人群X線交錯(cuò)互補(bǔ)修復(fù)基因1 Arg399Gln多態(tài)性與胃癌易感性關(guān)系的Meta分析[J];蘭州大學(xué)學(xué)報(bào)(醫(yī)學(xué)版);2015年03期

2 王超;任彩麗;王宏革;劉睿;張志;張潔;;XRCC1基因和ERCC2基因多態(tài)與胃癌的研究[J];現(xiàn)代預(yù)防醫(yī)學(xué);2014年15期

3 成莉;李琳;邢輝;;XRCC1基因多態(tài)性與卵巢癌對鉑類藥物化療敏感性的相關(guān)性研究[J];臨床腫瘤學(xué)雜志;2014年04期

4 樊曉妹;李魁秀;牛書懷;房朝輝;劉紅;;XRCC1基因多態(tài)性與宮頸癌發(fā)病風(fēng)險(xiǎn)及臨床病理因素的關(guān)系[J];中華醫(yī)學(xué)雜志;2013年43期

5 韓光明;申茂艷;劉艷霞;;中國人群非小細(xì)胞肺癌XRCC1基因多態(tài)性與鉑類藥物敏感性的Meta分析[J];中國藥業(yè);2013年20期

6 劉仕鵬;鄒紹靜;趙建強(qiáng);周保祥;汪忠紅;賈華鋒;袁開勝;何敬東;;XRCC1基因單核苷酸多態(tài)性與食管癌易感性的關(guān)系[J];實(shí)用腫瘤雜志;2013年03期

7 韓婧;李江;;DNA修復(fù)相關(guān)基因啟動(dòng)子甲基化和腫瘤化療耐藥的進(jìn)展[J];上海交通大學(xué)學(xué)報(bào)(醫(yī)學(xué)版);2011年01期

8 曾小云;余紅平;仇小強(qiáng);紀(jì)龍;李龍Z，

本文編號：1801765